The rise of Viagra and its effect on the drug landscape presents a intricate question for shareholders. While the first sales data were remarkable, the patent has lapsed, leading to a deluge of copycat alternatives that are reducing revenue. Furthermore, the industry is facing issues related to aging trends and evolving healthcare policies, making